← Back to Clinical Trials
Recruiting NCT05632887

NCT05632887 The Effect of Eyeliner on Tear Composition, Tear Secretion and Tear Film Stability.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05632887
Status Recruiting
Phase
Sponsor Zhongnan Hospital
Condition Dry Eye
Study Type OBSERVATIONAL
Enrollment 80 participants
Start Date 2022-11-20
Primary Completion 2026-09-15

Eligibility & Interventions

Sex Female only
Min Age 20 Years
Max Age 35 Years
Study Type OBSERVATIONAL
Interventions
no intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 80 participants in total. It began in 2022-11-20 with a primary completion date of 2026-09-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Eyeliner is one of the most common eye cosmetics. The main ingredients are titanium oxide, pigment, grease and preservative. The user will apply the eyeliner to the eyelid and eyelash. With the blinking again and again, the components of the eyeliner may enter the tear film and continue to act on the eye surface. Therefore, the investigators suspect that the use of eyeliner may be an important factor leading to dry eye disease. In order to explore the relationship between the use of eyeliner and dry eye disease, the investigators plan to collect eye surface characteristic data of the two groups of people who use eyeliner and who do not use it.Then use Raman analysis to explore whether the use of eyeliner will lead to changes in tear composition.The investigators intend to analyze the difference of tear composition between the two groups to understand the relationship between the change of tear composition and tear film stability.So that the investigators can identify the risk factors of dry eye disease, and provide basis for prevention and early treatment.

Eligibility Criteria

Inclusion Criteria: * People aged 20-35 who use eyeliner or do not use eyeliner . * People who use eyeliner have used it for ≥ 1 year; Frequency ≥ 3 times/week. Exclusion Criteria: * Other serious systemic diseases. * Other systemic diseases related to ocular surface, such as rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome and other immune system diseases or other eye diseases, history of eye surgery and trauma. * Lactating women or pregnant women. * Use electronic products for more than 4 hours every day. * Patients with circadian rhythm disorder. * People with radiation exposure history. * Non permanent residents in Wuhan.

Contact & Investigator

Central Contact

Min Ke

✉ keminyk@163.com

📞 +86 18672395959

Principal Investigator

Min Ke

STUDY CHAIR

Ophthalmology Department of Zhongnan Hospital of Wuhan University

Frequently Asked Questions

Who can join the NCT05632887 clinical trial?

This trial is open to female participants only, aged 20 Years or older, up to 35 Years, studying Dry Eye. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05632887 currently recruiting?

Yes, NCT05632887 is actively recruiting participants. Contact the research team at keminyk@163.com for enrollment information.

Where is the NCT05632887 trial being conducted?

This trial is being conducted at Wuhan, China.

Who is sponsoring the NCT05632887 clinical trial?

NCT05632887 is sponsored by Zhongnan Hospital. The principal investigator is Min Ke at Ophthalmology Department of Zhongnan Hospital of Wuhan University. The trial plans to enroll 80 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology